Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

HIV Infection

Free Subscription Articles published in J Virol Retrieve available abstracts of 82 articles: HTML format

Single Articles

July 2025
1. SUN Y, Yang C, Liu P, Cong Z, et al
   Novel insights into immune checkpoints in HIV/SHIV infection: from SHIV(SF162P3)-infected elite controllers to therapeutic strategy.
   J Virol. 2025 Jul 10:e0078525. doi: 10.1128/jvi.00785.
   PubMed     Abstract available
   
   
   
2. JANSSENS J, Isbell C, Kim SJ, Wedrychowski A, et al
   Differential decreases in various HIV DNA regions and HIV transcripts after ART initiation during chronic infection.
   J Virol. 2025 Jul 8:e0068325. doi: 10.1128/jvi.00683.
   PubMed     Abstract available
   
   
   
3. TORGBOR C, Thorley-Lawson DA, Moormann AM
   Epstein-Barr virus-infected tonsillar marginal zone B cells in vivo as a precursor for immunosuppression-related B-cell lymphoma.
   J Virol. 2025 Jul 8:e0105124. doi: 10.1128/jvi.01051.
   PubMed     Abstract available
   
   
   June 2025
4. ISMAIL SD, Sebaa S, Abrahams B, Nason MC, et al
   The role of Nef in the long-term persistence of the replication-competent HIV reservoir in South African women.
   J Virol. 2025 Jun 24:e0021725. doi: 10.1128/jvi.00217.
   PubMed     Abstract available
   
   
   
5. COTTIGNIES-CALAMARTE A, Marteau F, He F, Belouzard S, et al
   Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response.
   J Virol. 2025 Jun 12:e0039425. doi: 10.1128/jvi.00394.
   PubMed     Abstract available
   
   
   
6. SCHIFFER JT, Mudd JC, Antar AAR, Spivak AM, et al
   Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure.
   J Virol. 2025 Jun 4:e0071425. doi: 10.1128/jvi.00714.
   PubMed     Abstract available
   
   
   May 2025
7. SUTAR J, Jayal P, Mullick R, Chaudhary S, et al
   Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies.
   J Virol. 2025 May 16:e0000825. doi: 10.1128/jvi.00008.
   PubMed     Abstract available
   
   
   
8. GREBER UF
   Clicking viruses-with chemistry toward mechanisms in infection.
   J Virol. 2025 May 14:e0047125. doi: 10.1128/jvi.00471.
   PubMed     Abstract available
   
   
   
9. NIKOLAITCHIK OA, Chameettachal A, Islam S, Cheng Z, et al
   How to recover from a bad start: adaptation of HIV-1 transcription start site mutants during serial passaging in culture.
   J Virol. 2025 May 7:e0015925. doi: 10.1128/jvi.00159.
   PubMed     Abstract available
   
   
   April 2025
10. FAN T-J, Xie C, Li L, Jin X, et al
    HIV-1 Nef activates proviral DNA transcription by recruiting Src kinase to phosphorylate host protein Nef-associated factor 1 to compromise its viral restrictive function.
    J Virol. 2025 Apr 24:e0028025. doi: 10.1128/jvi.00280.
    PubMed     Abstract available
    
    
    
11. RADFORD CE, Bloom JD
    Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains.
    J Virol. 2025 Apr 22:e0019525. doi: 10.1128/jvi.00195.
    PubMed     Abstract available
    
    
    
12. LARROUS P, Garnier C, Morel M, Martin MM, et al
    Deciphering lentiviral Vpr/Vpx determinants required for HUSH and SAMHD1 antagonism highlights the molecular plasticity of these evolutionary conflicts.
    J Virol. 2025 Apr 22:e0019825. doi: 10.1128/jvi.00198.
    PubMed     Abstract available
    
    
    
13. MOORAD R, Peng A, Landis J, Pluta LJ, et al
    Genome evolution of Kaposi sarcoma-associated herpesvirus (KSHV).
    J Virol. 2025 Apr 16:e0195024. doi: 10.1128/jvi.01950.
    PubMed     Abstract available
    
    
    
14. GROVES NS, Clark AR, Aguilar RS, Hikichi Y, et al
    A monomeric envelope glycoprotein cytoplasmic tail is sufficient for HIV-1 Gag lattice trapping and incorporation.
    J Virol. 2025 Apr 15:e0210524. doi: 10.1128/jvi.02105.
    PubMed     Abstract available
    
    
    
15. HUANG Y, Liang G, Wang T, Ma Y, et al
    Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antivirals.
    J Virol. 2025 Apr 10:e0228924. doi: 10.1128/jvi.02289.
    PubMed     Abstract available
    
    
    
16. WU C, Johnson NM, Yu S, Lo AS, et al
    Persistence of CMV-specific anti-HIV CAR T cells after adoptive immunotherapy.
    J Virol. 2025 Apr 10:e0193324. doi: 10.1128/jvi.01933.
    PubMed     Abstract available
    
    
    
17. CHAUDHURI E, Jang S, Chakraborty R, Radhakrishnan R, et al
    CPSF6 promotes HIV-1 preintegration complex function.
    J Virol. 2025 Apr 9:e0049025. doi: 10.1128/jvi.00490.
    PubMed     Abstract available
    
    
    
18. VIOX EG, Richard J, Grandea AG 3rd, Nguyen K, et al
    Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques.
    J Virol. 2025 Apr 7:e0006225. doi: 10.1128/jvi.00062.
    PubMed     Abstract available
    
    
    March 2025
19. CHATTERJEE D, Niu L, Medjahed H, Ding S, et al
    A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120.
    J Virol. 2025 Mar 27:e0226724. doi: 10.1128/jvi.02267.
    PubMed     Abstract available
    
    
    
20. YAN H, Gao Y, Zhu Y, Chong H, et al
    Addition of a short HIV-1 fusion-inhibitory peptide to PRO 140 antibody dramatically increases its antiviral breadth and potency.
    J Virol. 2025 Mar 25:e0201824. doi: 10.1128/jvi.02018.
    PubMed     Abstract available
    
    
    
21. VICTORIA S, Leyens J, Meckes LM, Vavouras Syrigos G, et al
    CD4+ T cells facilitate replication of primary HIV-1 strains in macrophages and formation of macrophage internal virus-containing compartments.
    J Virol. 2025 Mar 25:e0018225. doi: 10.1128/jvi.00182.
    PubMed     Abstract available
    
    
    
22. HSIEH S-H, Huang K-J, Wang C-T
    A virus-like particle assembly system for probing the HIV-1 Gag-Pol dimerization domain: supporting evidence for reverse transcriptase involvement in protease activation by influencing Gag-Pol/Gag-Pol interaction.
    J Virol. 2025 Mar 12:e0223624. doi: 10.1128/jvi.02236.
    PubMed     Abstract available
    
    
    
23. TURNER A-MW, Bashore FM, Falcinelli SD, Fox JA, et al
    BET degraders reveal BRD4 disruption of 7SK and P-TEFb is critical for effective reactivation of latent HIV in CD4+ T-cells.
    J Virol. 2025 Mar 11:e0177724. doi: 10.1128/jvi.01777.
    PubMed     Abstract available
    
    
    
24. GC K, Lesko S, Emery A, Burnett C, et al
    HIV-1 single-transcription start-site mutants display complementary replication functions that are restored by reversion.
    J Virol. 2025 Mar 4:e0213924. doi: 10.1128/jvi.02139.
    PubMed     Abstract available
    
    
    
25. JANEVSKA M, Witkowski W, Vermeire J, Borowicz M, et al
    Impairment of endocytosis-related factors FNBP1L, ARHGAP24, and ATP6V1B1 increases HIV-1 entry into dendritic cells.
    J Virol. 2025 Mar 3:e0206624. doi: 10.1128/jvi.02066.
    PubMed     Abstract available
    
    
    February 2025
26. GOLAS G, Park BS, Wong SW
    Glycoproteins gM and gN are indispensable factors for rhesus macaque rhadinovirus replication and spread but can be reconstituted by KSHV chimeras.
    J Virol. 2025 Feb 25:e0192224. doi: 10.1128/jvi.01922.
    PubMed     Abstract available
    
    
    
27. GUERRERO JF, Zimdars LL, Bruce JW, Becker JT, et al
    Single-cell delineation of strain-specific HIV-1 Vif activities using dual reporter sensor cells and live cell imaging.
    J Virol. 2025 Feb 25:e0157924. doi: 10.1128/jvi.01579.
    PubMed     Abstract available
    
    
    
28. XU M, Hu H, Yang W, Zhang J, et al
    FBXO45 restricts HIV-1 replication by inducing SQSTM1/p62-mediated autophagic degradation of Tat.
    J Virol. 2025 Feb 12:e0191224. doi: 10.1128/jvi.01912.
    PubMed     Abstract available
    
    
    
29. WILLIAMS EP, Xue Y, Vogel P, Yang D, et al
    The antiviral BDGR-49 provides protection from lethal, neurotropic Venezuelan equine encephalitis virus intranasal infection in mice.
    J Virol. 2025 Feb 12:e0167924. doi: 10.1128/jvi.01679.
    PubMed     Abstract available
    
    
    
30. MITCHELL JL, Buranapraditkun S, Gantner P, Takata H, et al
    Activation of CXCR3(+) Tfh cells and B cells in lymph nodes during acute HIV-1 infection correlates with HIV-specific antibody development.
    J Virol. 2025 Feb 11:e0153224. doi: 10.1128/jvi.01532.
    PubMed     Abstract available
    
    
    
31. LI M, Yu F, Zhu B, Xiao J, et al
    Interactions between human immunodeficiency virus and human endogenous retroviruses.
    J Virol. 2025 Feb 7:e0231924. doi: 10.1128/jvi.02319.
    PubMed     Abstract available
    
    
    
32. ANG CG, Hyatt NL, Le Minh G, Gupta M, et al
    Conformational activation and disulfide exchange in HIV-1 Env induce cell-free lytic/fusogenic transformation and enhance infection.
    J Virol. 2025 Feb 6:e0147124. doi: 10.1128/jvi.01471.
    PubMed     Abstract available
    
    
    
33. HUDSON A, Wu P, Kroll KW, Hueber B, et al
    Longitudinal analysis of rhesus macaque metabolome during acute SIV infection reveals disruption in broad metabolite classes.
    J Virol. 2025 Feb 6:e0163424. doi: 10.1128/jvi.01634.
    PubMed     Abstract available
    
    
    
34. JANSSENS J, Wedrychowski A, Kim SJ, Isbell C, et al
    Longitudinal changes in the transcriptionally active and intact HIV reservoir after starting ART during acute infection.
    J Virol. 2025 Feb 5:e0143124. doi: 10.1128/jvi.01431.
    PubMed     Abstract available
    
    
    
35. PASCOE RD, Kim Y, Rhodes A, Ong J, et al
    Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoir.
    J Virol. 2025 Feb 4:e0167624. doi: 10.1128/jvi.01676.
    PubMed     Abstract available
    
    
    January 2025
36. KAJASTE-RUDNITSKI A, Marelli SS, Pultrone C, Pertel T, et al
    Correction for Kajaste-Rudnitski et al., "TRIM22 Inhibits HIV-1 Transcription Independently of Its E3 Ubiquitin Ligase Activity, Tat, and NF-kappaB-Responsive Long Terminal Repeat Elements".
    J Virol. 2025 Jan 27:e0207124. doi: 10.1128/jvi.02071.
    PubMed    
    
    
    
37. ARA A, Love RP, Follack TB, Ahmed KA, et al
    Erratum for Ara et al., "Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G".
    J Virol. 2025 Jan 16:e0220424. doi: 10.1128/jvi.02204.
    PubMed    
    
    
    
38. FAYYAZ S, Lotke R, Haussmann I, Petersen M, et al
    Reactivation of latent HIV-1 by the glucocorticoid receptor modulator AZD9567.
    J Virol. 2025 Jan 16:e0188624. doi: 10.1128/jvi.01886.
    PubMed     Abstract available
    
    
    
39. COHEN P, Lambson BE, Mkhize NN, Moodley C, et al
    Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.
    J Virol. 2025 Jan 16:e0173024. doi: 10.1128/jvi.01730.
    PubMed     Abstract available
    
    
    
40. LICHON DM, LoMascolo NJ, Mounce BC, Campbell EM, et al
    Microtubule acetylation is not required for HIV-1 infection or TRIM69-mediated restriction of HIV-1 infection.
    J Virol. 2025 Jan 13:e0102624. doi: 10.1128/jvi.01026.
    PubMed     Abstract available
    
    
    December 2024
41. COUNCIL OD, Tyers L, Moeser M, Sondgeroth A, et al
    The persistent pool of HIV-1-infected cells is formed episodically during untreated infection.
    J Virol. 2024 Dec 26:e0097924. doi: 10.1128/jvi.00979.
    PubMed     Abstract available
    
    
    
42. GABA A, Yousefi M, Bhattacharjee S, Chelico L, et al
    Variability in HIV-1 transmitted/founder virus susceptibility to combined APOBEC3F and APOBEC3G host restriction.
    J Virol. 2024 Dec 23:e0160624. doi: 10.1128/jvi.01606.
    PubMed     Abstract available
    
    
    
43. CHEN C, Zhong Z, Zhang W, Xia B, et al
    Tannic acid reactivates HIV-1 latency by mediating CBX4 degradation.
    J Virol. 2024 Dec 18:e0117324. doi: 10.1128/jvi.01173.
    PubMed     Abstract available
    
    
    
44. CHEN K, Zhou B, Wang X, Yang G, et al
    Equine lentivirus Gag protein degrades mitochondrial antiviral signaling protein via the E3 ubiquitin ligase Smurf1.
    J Virol. 2024 Dec 12:e0169124. doi: 10.1128/jvi.01691.
    PubMed     Abstract available
    
    
    
45. CUI W, Wang H, Gao Y, Zhang X, et al
    Deubiquitinase USP37 enhances the anti-HIV-2/SIV ability of the host restriction factor SAMHD1.
    J Virol. 2024 Dec 10:e0185824. doi: 10.1128/jvi.01858.
    PubMed     Abstract available
    
    
    
46. TAKAHAMA S, Washizaki A, Okamura T, Kitamura S, et al
    The quality of SIV-specific fCD8 T cells limits SIV RNA production in Tfh cells during antiretroviral therapy.
    J Virol. 2024 Dec 6:e0081224. doi: 10.1128/jvi.00812.
    PubMed     Abstract available
    
    
    November 2024
47. DING H, Nguyen HT, Li W, Deshpande A, et al
    Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation.
    J Virol. 2024 Nov 7:e0172024. doi: 10.1128/jvi.01720.
    PubMed     Abstract available
    
    
    
48. STEVENS CS, Carmichael JC, Watkinson R, Kowdle S, et al
    A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing.
    J Virol. 2024 Nov 4:e0083224. doi: 10.1128/jvi.00832.
    PubMed     Abstract available
    
    
    October 2024
49. PADRON A, Dwivedi R, Chakraborty R, Prakash P, et al
    Cyclophilin A facilitates HIV-1 integration.
    J Virol. 2024 Oct 31:e0094724. doi: 10.1128/jvi.00947.
    PubMed     Abstract available
    
    
    
50. HE W-Q, Pang W, Li N, Li A-Q, et al
    IFI27 inhibits HIV-1 replication by degrading Gag protein through the ubiquitin-proteasome pathway.
    J Virol. 2024 Oct 30:e0135624. doi: 10.1128/jvi.01356.
    PubMed     Abstract available
    
    
    
51. LADINSKY MS, Zhu L, Ullah I, Uchil PD, et al
    Electron tomography visualization of HIV-1 virions trapped by fusion inhibitors to host cells in infected tissues.
    J Virol. 2024 Oct 30:e0143224. doi: 10.1128/jvi.01432.
    PubMed     Abstract available
    
    
    
52. HOGAN VA, Harmon J, Cid-Rosas M, Hall LR, et al
    Conserved residues of the immunosuppressive domain of MLV are essential for regulating the fusion-critical SU-TM disulfide bond.
    J Virol. 2024 Oct 29:e0098924. doi: 10.1128/jvi.00989.
    PubMed     Abstract available
    
    
    September 2024
53. CHENG Z, Islam S, Kanlong JG, Sheppard M, et al
    Translation of HIV-1 unspliced RNA is regulated by 5' untranslated region structure.
    J Virol. 2024 Sep 24:e0116024. doi: 10.1128/jvi.01160.
    PubMed     Abstract available
    
    
    
54. PINCUS SH, Cole FM, Ober K, Tokmina-Lukaszewska M, et al
    Conjugation of anti-HIV gp41 monoclonal antibody to a drug capable of targeting resting lymphocytes produces an effective cytotoxic anti-HIV immunoconjugate.
    J Virol. 2024 Sep 16:e0064724. doi: 10.1128/jvi.00647.
    PubMed     Abstract available
    
    
    
55. JANEVSKA M, Cammaert T, Naessens E, Verhasselt B, et al
    A cGAS-mediated type I interferon response in human CD4+ T cells depends on productive infection and is conserved over HIV types and strains.
    J Virol. 2024 Sep 13:e0087724. doi: 10.1128/jvi.00877.
    PubMed     Abstract available
    
    
    
56. ZANKHARIA U, Yi Y, Lu F, Vladimirova O, et al
    HIV-induced RSAD2/Viperin supports sustained infection of monocyte-derived macrophages.
    J Virol. 2024 Sep 11:e0086324. doi: 10.1128/jvi.00863.
    PubMed     Abstract available
    
    
    
57. MARCHITTO L, Richard J, Prevost J, Tauzin A, et al
    The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity.
    J Virol. 2024 Sep 9:e0101624. doi: 10.1128/jvi.01016.
    PubMed     Abstract available
    
    
    
58. ZHANG S, Anang S, Zhang Z, Nguyen HT, et al
    Conformations of membrane human immunodeficiency virus (HIV-1) envelope glycoproteins solubilized in Amphipol A18 lipid-nanodiscs.
    J Virol. 2024 Sep 9:e0063124. doi: 10.1128/jvi.00631.
    PubMed     Abstract available
    
    
    
59. AGRAWAL P, Knudsen ML, MacCamy A, Hurlburt NK, et al
    Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env.
    J Virol. 2024 Sep 6:e0074424. doi: 10.1128/jvi.00744.
    PubMed     Abstract available
    
    
    
60. TAUZIN A, Marchitto L, Belanger E, Benlarbi M, et al
    Three families of CD4-induced antibodies are associated with the capacity of plasma from people living with HIV to mediate ADCC in the presence of CD4-mimetics.
    J Virol. 2024 Sep 4:e0096024. doi: 10.1128/jvi.00960.
    PubMed     Abstract available
    
    
    
61. ZHANG W, Nilles TL, Bream JH, Li H, et al
    Breadth and polyfunctionality of T cell responses to human cytomegalovirus in men who have sex with men: relationship with HIV infection and frailty.
    J Virol. 2024 Sep 4:e0116724. doi: 10.1128/jvi.01167.
    PubMed     Abstract available
    
    
    August 2024
62. BRACKENRIDGE S, John N, He W, Fruh K, et al
    Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins.
    J Virol. 2024 Aug 29:e0120624. doi: 10.1128/jvi.01206.
    PubMed     Abstract available
    
    
    
63. ZHANG Y, Zhang M, Wu H, Wu X, et al
    Afucosylated anti-EBOV antibody MIL77-3 engages sGP to elicit NK cytotoxicity.
    J Virol. 2024 Aug 20:e0068524. doi: 10.1128/jvi.00685.
    PubMed     Abstract available
    
    
    
64. BARBOSA BOMFIM CC, Genin H, Cottoignies-Callamarte A, Gallois-Montbrun S, et al
    CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients.
    J Virol. 2024 Aug 20:e0012824. doi: 10.1128/jvi.00128.
    PubMed     Abstract available
    
    
    
65. MUECKSCH F, Klaus S, Laketa V, Muller B, et al
    Probing Gag-Env dynamics at HIV-1 assembly sites using live-cell microscopy.
    J Virol. 2024 Aug 13:e0064924. doi: 10.1128/jvi.00649.
    PubMed     Abstract available
    
    
    
66. MU Z, Whitley J, Martik D, Sutherland L, et al
    Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.
    J Virol. 2024 Aug 13:e0013724. doi: 10.1128/jvi.00137.
    PubMed     Abstract available
    
    
    July 2024
67. ZHOU M, Yang T, Yuan M, Li X, et al
    ORC1 enhances repressive epigenetic modifications on HIV-1 LTR to promote HIV-1 latency.
    J Virol. 2024 Jul 31:e0003524. doi: 10.1128/jvi.00035.
    PubMed     Abstract available
    
    
    
68. NELSON GW, van Duijn J, Yuki Y, Pau MG, et al
    Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.
    J Virol. 2024 Jul 24:e0028124. doi: 10.1128/jvi.00281.
    PubMed     Abstract available
    
    
    
69. REYES BALLISTA JM, Hoover AJ, Noble JT, Acciani MD, et al
    Chikungunya virus release is reduced by TIM-1 receptors through binding of envelope phosphatidylserine.
    J Virol. 2024 Jul 15:e0077524. doi: 10.1128/jvi.00775.
    PubMed     Abstract available
    
    
    June 2024
70. KUSE N, Noyori O, Takahashi N, Zhang Y, et al
    Recognition of HIV-1-infected fibrocytes lacking Nef-mediated HLA-B downregulation by HIV-1-specific T cells.
    J Virol. 2024 Jun 28:e0079124. doi: 10.1128/jvi.00791.
    PubMed     Abstract available
    
    
    
71. ROESMANN F, Sertznig H, Klaassen K, Wilhelm A, et al
    The interferon-regulated host factor hnRNPA0 modulates HIV-1 production by interference with LTR activity, mRNA trafficking, and programmed ribosomal frameshifting.
    J Virol. 2024 Jun 20:e0053424. doi: 10.1128/jvi.00534.
    PubMed     Abstract available
    
    
    
72. BOOPATHY AV, Nekkalapudi A, Sung J, Schulha S, et al
    Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.
    J Virol. 2024 Jun 3:e0029424. doi: 10.1128/jvi.00294.
    PubMed     Abstract available
    
    
    May 2024
73. NAZZIWA J, Andrews SM, Hou MM, Bruhn CAW, et al
    Higher HIV-1 evolutionary rate is associated with cytotoxic T lymphocyte escape mutations in infants.
    J Virol. 2024 May 30:e0007224. doi: 10.1128/jvi.00072.
    PubMed     Abstract available
    
    
    
74. DEKKER JG, Klaver B, Berkhout B, Das AT, et al
    Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.
    J Virol. 2024 May 24:e0033524. doi: 10.1128/jvi.00335.
    PubMed    
    
    
    
75. RAHMBERG AR, Markowitz TE, Mudd JC, Ortiz AM, et al
    SIV infection and ARV treatment reshape the transcriptional and epigenetic profile of naive and memory T cells in vivo.
    J Virol. 2024 May 23:e0028324. doi: 10.1128/jvi.00283.
    PubMed     Abstract available
    
    
    
76. WEBB GM, Pessoa CT, McCullen AJ, Hwang JM, et al
    Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection.
    J Virol. 2024 May 22:e0027324. doi: 10.1128/jvi.00273.
    PubMed     Abstract available
    
    
    
77. VERBEEK R, Vandekerckhove L, Van Cleemput J
    Update on human herpesvirus 7 pathogenesis and clinical aspects as a roadmap for future research.
    J Virol. 2024 May 8:e0043724. doi: 10.1128/jvi.00437.
    PubMed     Abstract available
    
    
    April 2024
78. PERSAUD AT, Khela J, Fernandes C, Chaphekar D, et al
    Virion-incorporated CD14 enables HIV-1 to bind LPS and initiate TLR4 signaling in immune cells.
    J Virol. 2024 Apr 25:e0036324. doi: 10.1128/jvi.00363.
    PubMed     Abstract available
    
    
    
79. YANG Q, Wang J, Chen Z
    Conditional splicing system for tight control of viral overlapping genes.
    J Virol. 2024;98:e0024224.
    PubMed     Abstract available
    
    
    March 2024
80. VON MALTITZ P, Wettstein L, Weil T, Schommers P, et al
    Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodies.
    J Virol. 2024 Mar 19:e0119023. doi: 10.1128/jvi.01190.
    PubMed     Abstract available
    
    
    
81. TWENTYMAN J, Emerman M, Ohainle M
    Capsid-dependent lentiviral restrictions.
    J Virol. 2024 Mar 18:e0030824. doi: 10.1128/jvi.00308.
    PubMed     Abstract available
    
    
    February 2024
82. JOSHI VR, Claiborne DT, Pack ML, Power KA, et al
    A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.
    J Virol. 2024 Feb 27:e0172023. doi: 10.1128/jvi.01720.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.